Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement

Pharmaceutical Development and Technology

Volumn 16, Issue 3, 2011, Pages 187-200

  Murdande, Sharad B ^a,b   Pikal, Michael J ^a   Shanker, Ravi M ^b   Bogner, Robin H ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b PFIZER INC   (United States)

Author keywords

amorphous; crystal; dissolution rate; high throughput; kinetic solubility; partially crystalline; Solubility; thermodynamic solubility

Indexed keywords

ATTAPULGITE; CALCIUM SILICATE; CYCLODEXTRIN; DICLOFENAC; DIMETHYL SULFOXIDE; DRUG CARRIER; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LIPID; ORGANIC SOLVENT; POVIDONE; SILICON DIOXIDE; WATER;

AQUEOUS SOLUTION; CRYSTALLIZATION; DISPERSION; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; INFRARED SPECTROSCOPY; IONIZATION; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SOLID; SOLID STATE; SOLUBILITY; THERMAL ANALYSIS; THERMODYNAMICS; ULTRAVIOLET SPECTROPHOTOMETRY; X RAY DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG DISCOVERY; DRUG STABILITY; PHARMACEUTICAL PREPARATIONS; PHASE TRANSITION; PHYSICOCHEMICAL PHENOMENA; SOLUBILITY; THERMODYNAMICS; WATER;

EID: 78651304897     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837451003774377     Document Type: Review

References (91)

1. Grant DJW, Higuchi T. Solubility behavior of organic compounds. New York: John Wiley & Sons; 1990.
2. Yalkowski SH, Banerjee S. Aqueous solubility: Methods of estimation for organic compounds. New York: Marcel Dekker; 1992.
3. Higuchi T, Mei FL, Kimura STJ, Rytting H. Solubility determination of barely aqueous-soluble organic solids. J Pharmaceut Sci 1979;68(10):1267-1272. (Pubitemid 10247638)
4. Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliv Rev 2001;48(1):3-26. (Pubitemid 32452290)
5. Threlfall TL. Analysis of organic polymorphs: A review. Analyst 1995;120:2435-2460.
6. Yalkowski SH. Solubility and solubilization in aqueous media. Washington, DC: Oxford University Press; 1999.
7. Grant DJW, Higuchi T. Solubility behaviour of organic compounds. New York: Wiley; 1990.
8. Singhal D, Curatolo W. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 2004;56(3):335-347. (Pubitemid 38201429)
9. Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharmaceut Sci 2005;94(5):929-939. (Pubitemid 40780760)
10. Carlton RA. Experimental methods in the study of thermodynamic polymorph stability relationships. Am Pharmaceut Rev 2006;9(1):88,90-93,99.
11. Cruz Cabeza AJ, Day GM, Motherwell WDS, Jones W. Amide pyramidalization in carbamazepine: A flexibility problem in crystal structure prediction? Crystal Growth Des 2006;6(8):1858-1866. (Pubitemid 44320185)
12. Day GM, Van de Streek J, Bonnet A, Burley JC, Jones W, Motherwell WDS. Polymorphism of scyllo-inositol: Joining crystal structure prediction with experiment to elucidate the structures of two polymorphs. Crystal Growth Des 2006;6(10):2301-2307. (Pubitemid 44629538)
13. Brittain HG. Spectral methods for the characterization of polymorphs and solvates. J Pharmaceut Sci 1997;86(4):405-412. (Pubitemid 27154753)
14. Giron D. Monitoring polymorphism of drugs, an on-going challenge. Part 1. Am Pharmaceut Rev 2008;11(1):66-71.
15. Giron D. Monitoring polymorphism of drugs, an on-going challenge. Part 2. Am Pharmaceut Rev 2008;11(3):86-90.
16. Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharmaceut Sci 2006;95(8):1641-1665. (Pubitemid 44229572)
17. Bahl D, Bogner R. Amorphization of indomethacin by co-grinding with Neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharmaceut Res 2006;23(10):2317-2325. (Pubitemid 44511512)
18. Huttenrauch R. Molecular galenics as the basis of modern drug formation. Acta Pharmaceut Technol 1978;6:55-127.
19. Corrigan OI, Holohan EM, Sabra K. Amorphous forms of thiazide diuretics prepared by spray drying. Int J Pharmaceut 1984;18:195-200. (Pubitemid 14184798)
20. Sheen PC, Kim SI, Petillo JJ, Serajuddin ATM. Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans. J Pharmaceut Sci 1991;80:712-714.
21. Pozzi F, Longo A, Lazzarini C, Carenzi A. Formulations of ubidecarenone with improved bioavailability. Eur J Pharmaceut Biopharmaceut 1991;37:243-246.
22. Sheen PC, Khetarpal VK, Cariola CM, Rowlings CE. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int J Pharmaceut 1995;18:221-227.
23. Grantscharova E, Gutzow I. Vapour pressure, solubility and affinity of undercooled melts and glasses. J Non-Crystalline Solids 1986;81:99-127. (Pubitemid 16548343)
24. Hancock BC. Disordered drug delivery: Destiny, dynamics and the Deborah number. J Pharm Pharmacol 2002;54:737-746. (Pubitemid 34649460)
25. Shamblin SL, Tang X, Chang L, Hancock BC, Pikal MJ. Characterization of the time scales of molecular motion in pharmaceutically important glasses. J Phys Chem B 1999;103(20):4113-4121. (Pubitemid 129702538)
26. Kawakami K, Miyoshi K, Ida Y. Impact of the amount of excess solids on apparent solubility. Pharmaceut Res 2005;22(9):1537-1543. (Pubitemid 41215895)
27. Elamin AA, Ahlneck C, Ålderborn G, Nystrom C. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int J Pharmaceut 1994;111:159-170. (Pubitemid 24288892)
28. Bevan CD, Lloyd RS. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem 2000;72(8):1781-1787. (Pubitemid 30220169)
29. Kerns EH, Di L, Carter GT. In vitro solubility assays in drug discovery. Curr Drug Metabol 2008;9:879-885.
30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26. (Pubitemid 33653411)
31. Betigeri S, Thakur A, Shukla R, Raghavan K. Effect of polymer additives on the transformation of BMS-566394 anhydrate to the dihydrate form. Pharmaceut Res 2008;25(5):1043-1051. (Pubitemid 351521104)
32. Brewster ME, Vandecruys R, Peeters J, Neeskens P, Verreck G, Loftsson T. Comparative interaction of 2-hydroxypropyl- [beta]-cyclodextrin and sulfobutylether-[beta]-cyclodextrin with itraconazole: Phase-solubility behavior and stabilization of supersaturated drug solutions. Eur J Pharmaceut Sci 2008;34(2-3):94-103.
33. Thomas S, Brightman F, Gill H, Lee S, Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharmaceut Sci 2008;97(10):4557-4574.
34. Mosharraf M, Sebhatu T, Nystrom C. The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. Int J Pharmaceut 1999;177(1):29-51. (Pubitemid 29067426)
35. Watanabe T, Hasegawa S, Wakiyama N, Kusai A, Senna M. Prediction of apparent equilibrium solubility of indomethacin compounded with silica by 13C solid state NMR. Int J Pharmaceut 2002;248(1-2):123-129. (Pubitemid 35341416)
36. Weiner N. In: Pharmaceutical dosage forms - disperse systems. New York: Marcel Dekker, Inc; 1996.
37. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23(1-3):3-25. (Pubitemid 27046991)
38. Bahl D, Bogner R. 2008. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: The case of indomethacin. AAPS PharmSciTech 9(1):146-153.
39. Stuart M, Box K. Chasing equilibrium: Measuring the intrinsic solubility of weak acids and bases. Analyt Chem 2005;77:983-990. (Pubitemid 40261763)
40. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instr 1965;4:117-212.
41. Glomme A, Marz J, Dressman JB. Comparison of a miniaturized shake- flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J Pharmaceut Sci 2005;94(1):1-16. (Pubitemid 40116365)
42. Avdeef A. pH-metric solubility. 1: Solubility-pH profiles from Bjerrum plots. Gibbs buffer and pKa in the solid state. Pharm Pharmacol Communic 1998;4:165-178. (Pubitemid 28142433)
43. Avdeef A, Berger CM. pH-metric solubility. 3: Dissolution titration template method for solubility determination. Eur J Pharmaceut Sci 2001;14(4):281-291. (Pubitemid 33001620)
44. Avdeef A, Berger CM, Brownell C. pH-metric solubility. 2: Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharmaceut Res 2000;17(1):85-89. (Pubitemid 30121104)
45. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 2001;1:277-351.
46. Wood JH, Syarto JE, Letterman H. Improved holder for intrinsic dissolution rate studies. J Pharmaceut Sci 1965;54(7):1068.
47. Venkatesh S, Li J, Xu Y, Vishnuvajjala R, Anderson BD. Intrinsic solubility estimation and pH-solubility behavior of Cosalane (NSC 658586), an extremely hydrophobic diprotic acid. Pharmaceut Res 1996;13(10):1453-1459. (Pubitemid 26356945)
48. Yu LX, Carlin AS, Amidon GL, Hussain AS. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharmaceut 2003;270:221-227. (Pubitemid 38077102)
49. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. Dissolution kinetics of carboxylic acids I: Effect of pH under unbuffered conditions. J Pharmaceut Sci 1981;70:13-22. (Pubitemid 11187795)
50. McNamara DP, Amidon GL. Dissolution of acidic and basic compounds from the rotating disk: Influence of convective diffusion and reaction. J Pharmaceut Sci 1986;75(9):858-868. (Pubitemid 16000462)
51. McNamara DP, Amidon GL. Reaction plane approach for estimating the effects of buffers on the dissolution rate of acidic drugs. J Pharmaceut Sci 1988;77(6):511-517. (Pubitemid 19036940)
52. Stella VJ, Mooney KG, Pipkin JD. Dissolution and ionization of warfarin. J Pharmaceut Sci 1984;73(7):946-948.
53. Mooney KG, Rodriguez-gaxiola M, Mintun M, Himmelstein KJ, Stella VJ. Dissolution kinetics of phenylbutazone. J Pharmaceut Sci 1981;70(12):1358-1365. (Pubitemid 12190072)
54. Box KJ, Völgyi G, Baka E, Stuart M, Takács-Novák K, Comer JEA. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution - a validation study. J Pharmaceut Sci 2006;95(6):1298-1307. (Pubitemid 43874443)
55. Kibbey CE, Poole SK, Robinson B, Jackson JD, Durham D. An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. J Pharmaceut Sci 2001;90(8):1164-1175.
56. Dinter C, Schuetz A, Blume T, Weinmann H, Harre M, Neh H. Automated solubility determination using a customized robotic system and a turbidity probe. J Assoc Lab Automat 2005;10(6):408-411. (Pubitemid 43055617)
57. Kerns EH. High throughput physicochemical profiling for drug discovery. J Pharmaceut Sci 2001;90(11):1838-1858. (Pubitemid 33062605)
58. Avdeef A. High throughput measurements of solubility profiles. In: Testa B, van de Waterbeend H., Folkers G, Guy R, editors. Pharmacokinetic optimization in drug research; biological, physicochemical, and computational strategies. Weinheim: Verlag Helvetica Chimica Acta: Zurich and Wiley-VCH; 2001:305-326.
59. Seadeek C, Ando H, Bhattachar SN, Heimbach T, Sonnenberg JL, Blackburn AC. Automated approach to couple solubility with final pH and crystallinity for pharmaceutical discovery compounds. J Pharmaceut Biomed Anal 2007;43(5):1660-1666. (Pubitemid 46453084)
60. Dehring KA, Workman HL, Miller KD, Mandagere A, Poole SK. Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility. J Pharmaceut Biomedical Anal 2004;36(3):447-456. (Pubitemid 39441313)
61. Sugano K, Kato T, Suzuki K, Keiko K, Sujaku T, Mano T. High throughput solubility measurement with automated polarized light microscopy analysis. J Pharmaceuti Sci 2006;95(10):2115-2122. (Pubitemid 44568523)
62. Wyttenbach N, Alsenz J, Grassmann O. Miniaturized assay for solubility and residual solid screening (SORESOS) in early drug development. Pharmaceut Res 2007;24(5):888-898. (Pubitemid 46675389)
63. Vandecruys R, Peeters J, Verreck G, Brewster ME. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharmaceut 2007;342:168-175. (Pubitemid 47259339)
64. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharmaceut 2000;193(2):231-237. (Pubitemid 30001867)
65. Brewster ME, Vandecruys R, Verreck G, Peeters J. Supersaturating drug delivery systems: Effect of hydrophilic cyclodextrins and other excipient on the formation and stabilization of supersaturated drug solutions. Pharmazie 2008;63:217-220. (Pubitemid 351449932)
66. Yi Y, Hatziavramidis D, Myerson AS, Waldo M, Beylin VG, Mustakis J. Development of a small-scale automated solubility measurement apparatus. Industrial Engineer Chem Res 2005;44(15):5427-5433. (Pubitemid 41057066)
67. Wang Z, Burrell LS, Lambert WJ. Solubility of E2050 at various pH: A case in which apparent solubility is affected by the amount of excess solid. J Pharmaceut Sci 2002;91(6):1445-1455. (Pubitemid 34633960)
68. ACD, Labs. ACD pKa database. 8.00 ed., 90 Adelaide Street, West Toronto, M5H3V9, Canada: Advanced Chemistry Development Inc.
69. Chen J, Brooks CL, Scheraga HA. Revisiting the carboxylic acid dimers in aqueous solution: Interplay of hydrogen bonding, hydrophobic interactions, and entropy. J Phys Chem B 2008;112(2):242-249. (Pubitemid 351184597)
70. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharmaceut Res 1997;14(12):1691-1698. (Pubitemid 28062912)
71. Baka E, Comer JEA, Takács-Novák K. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J Pharmaceut Biomed Anal 2008; 46:335-341.
72. Mosharraf M, Nystrom C. Apparent solubility of drugs in partially crystalline systems. Drug Develop Industrial Pharm 2003;29(6):603-622. (Pubitemid 36835154)
73. Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Mol Pharmaceut 2004;1(6):406-413.
74. Chawla G, Bansal AK. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharmaceut Sci 2007;32(1):45-57. (Pubitemid 47411498)
75. Chiou WL. Pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous solubility studies on griseofulvin-polyethylene glycol 6000 systems. J Pharmaceut Sci 1977;66(7):989-991. (Pubitemid 8128487)
76. Sekiguchi K, Obi N. Absorption of eutectic mixtures. I. A comparison of the behavior of a eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 1961;9:866-872.
77. Ford JL. The current status of solid dispersions. Pharm Acta Helv 1986;61(3):69-88. (Pubitemid 16134014)
78. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12(23-24):1068-1075. (Pubitemid 350186132)
79. Ruan L-P, Yu B-Y, Fu G-M, Zhu D-N. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J Pharmaceut Biomed Anal 2005;38(3):457-464. (Pubitemid 40733182)
80. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharmaceut Biopharmaceut 2000;50(1):47-60. (Pubitemid 30326688)
81. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharmaceut Sci 1999;88(10):1058-1066.
82. Damian F, Blaton N, Kinget R, Van den Mooter G. Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire 44/14 and PVP K30. Int J Pharmaceut 2002;244:87-98. (Pubitemid 35245449)
83. Yokoi Y, Yonemochi E, Terada K. Changes in surface properties by granulation and physicochemical stability of granulated amorphous cefditoren pivoxil with additives. Int J Pharmaceut 2004;280:67-75. (Pubitemid 38950905)
84. Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous vÅldecoxib. Int J Pharmaceut 2004;282(1-2):151-162.
85. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. Stability of amorphous indomethacin compounded with silica. Int J Pharmaceut 2001;226:81-91. (Pubitemid 32800785)
86. Gupta MK, Tseng Y-C, Goldman D, Bogner RH. Hydrogen bonding with adsorbent during storage governs drug dissolution from solid-dispersion granules. Pharmaceut Res 2002;19(11):1663-1672. (Pubitemid 35305518)
87. Li J, Guo Y, Zografi G. The solid-state stability of amorphous quinapril in the presence of beta-cyclodextrins. J Pharmaceut Sci 2002;91:229-243. (Pubitemid 34074481)
88. Loftsson T, Fririksdóttir H, Gumundsdóttir TK. The effect of water-soluble polymers on aqueous solubility of drugs. Int J Pharmaceut 1996;127(2):293-296. (Pubitemid 26092141)
89. Usui F, Maeda K, Kusai A, Nishimura K, Keiji Y. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharmaceuti 1997;154(1):59-66. (Pubitemid 27326820)
90. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharmaceut Res 2000;17(4):397-404. (Pubitemid 30395293)
91. Gupta P, Kakumanu VK, Bansal AK. Stability and solubility of Celecoxib-PVP amorphous dispersions: A molecular perspective. Pharmaceut Res 2004;21(10):1762-1769. (Pubitemid 39390086)